chitosan has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 15 (65.22) | 2.80 |
| Authors | Studies |
|---|---|
| Lei, B; Li, L; Li, Z; Liu, J; Liu, T; Pang, Y; Wang, W | 1 |
| Jang, ES; Jeong, MS; Manivasagan, P; Saravanakumar, K; Sathiyaseelan, A; Wang, MH | 1 |
| Ghahremani, F; Hosseini, M; Jolfaie, NA; Kefayat, A; Rafienia, M | 1 |
| Alvi, SB; Bantal, V; Jogdand, AB; Nazia, B; Rajalakshmi, PS; Rengan, AK | 1 |
| Adibfar, S; Gholizadeh Navashenaq, J; Hassannia, H; Hojjat-Farsangi, M; Izadi, S; Jadidi-Niaragh, F; Karpisheh, V; Masjedi, A; Mohammadi, H; Nazer, A; Rashidi, B; Tarokhian, H | 1 |
| Bozorgi, A; Bozorgi, M; Haghighi, Z; Khazaei, M; Khazaei, MR | 1 |
| ElSafy, S; Elshoky, HA; Mansour, S; Ramzy, A; Sebak, A; Soliman, A; Youness, R | 1 |
| Fang, M; Feng, L; Wang, W; Wen, J; Weng, J; Xie, J; Yan, Q; Yang, J; Zheng, G; Zheng, X | 1 |
| Bharathi, D; Djearamane, S; Lee, J; Nandagopal, JGT; Ranjithkumar, R; Wong, LS | 1 |
| Abduh, MS | 1 |
| Aalhate, M; Chatterjee, E; Gupta, U; Guru, SK; Kumar, R; Mahajan, S; Maji, I; Saren, BN; Singh, PK | 1 |
| Chen, X; Jiao, J; Li, S; Niu, S; Williams, GR; Wu, J; Zhang, X; Zhu, LM | 1 |
| Daniele, MA; Menegatti, S; Schneible, JD; Young, AT | 1 |
| Allard-Vannier, E; Aubrey, N; Chourpa, I; David, S; Hervé-Aubert, K; Lautram, N; Nguyen, PV; Passirani, C | 1 |
| Chen, D; Chen, Y; Cheng, K; Jiang, S; Lin, Z; Lu, M; Ming, L; Yang, R; Zhou, J | 1 |
| An, Y; Chen, D; Ding, Y; He, C; Hu, C; Liu, D; Liu, P; Tang, Q; Wang, X; Yang, R; Yu, W; Zhang, Z | 1 |
| Dhandapani, R; Handi, V; Manigandan, A; Radhakrishnan, J; Sethuraman, S; Subramanian, A; Sundaramoorthy, NS | 1 |
| Allard-Vannier, E; Ben Djemaa, S; Chourpa, I; David, S; Falanga, A; Galdiero, S; Hervé-Aubert, K; Munnier, E | 1 |
| Cheng, B; Gao, F; Maissy, E; Xu, P | 1 |
| Ahmadbeigi, N; Ebrahimi-Barough, S; Kamalabadi-Farahani, M; Roozafzoon, R; Soleimani, M; Vasei, M | 1 |
| Cao, M; Deng, X; Hu, K; Sheng, W; Wu, Y; Xiao, X; Yang, Y; Yin, Z; Zeng, Y; Zhang, J; Zhou, Z | 1 |
| Lin, J; Liu, C; Liu, H; Liu, T; Mao, ZW; Nie, S; Sun, Z; Xie, Y; Yang, Z | 1 |
| Bhanumathi, R; Bhattacharyya, A; Gunasekaran, P; Kannan, S; Murugan, C; Rayappan, K; Shanthi, K; Sivasubramanian, S; Thangam, R; Thirumurugan, R; Vivek, R | 1 |
23 other study(ies) available for chitosan and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells.
Topics: Cell Line, Tumor; Chitosan; Doxorubicin; Female; Humans; Integrin alphaVbeta3; Nanoparticles; Neoplastic Stem Cells; Particle Size; Peptides; Proteomics; Single-Cell Analysis; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2021 |
Folic acid conjugated chitosan encapsulated palladium nanoclusters for NIR triggered photothermal breast cancer treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Folic Acid; HEK293 Cells; Humans; Light; Nanoparticles; Palladium; Rutin; Temperature; Triple Negative Breast Neoplasms | 2022 |
Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment.
Topics: Animals; Chitosan; Folic Acid; Humans; Hydrogen-Ion Concentration; Mebendazole; Mice; Nanoparticles; Triple Negative Breast Neoplasms | 2022 |
Chitosan IR806 dye-based polyelectrolyte complex nanoparticles with mitoxantrone combination for effective chemo-photothermal therapy of metastatic triple-negative breast cancer.
Topics: Cell Line, Tumor; Chitosan; Doxorubicin; Humans; Hyperthermia, Induced; Mitoxantrone; Nanoparticles; Phototherapy; Photothermal Therapy; Polyelectrolytes; Triple Negative Breast Neoplasms | 2022 |
Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses.
Topics: Animals; Cell Line, Tumor; Chitosan; Enhancer of Zeste Homolog 2 Protein; Folic Acid; Humans; Magnetic Iron Oxide Nanoparticles; Mice; Nanoparticles; RNA, Small Interfering; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
The anti-cancer effect of chitosan/resveratrol polymeric nanocomplex against triple-negative breast cancer; an in vitro assessment.
Topics: bcl-2-Associated X Protein; Chitosan; Humans; Nanoparticles; Proto-Oncogene Proteins c-bcl-2; Resveratrol; Triple Negative Breast Neoplasms | 2023 |
Drugless nanoparticles tune-up an array of intertwined pathways contributing to immune checkpoint signaling and metabolic reprogramming in triple-negative breast cancer.
Topics: B7-H1 Antigen; Biocompatible Materials; Chitosan; Humans; Lecithins; Nanoparticles; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2022 |
Application of microneedles combined with dendritic cell-targeted nanovaccine delivery system in percutaneous immunotherapy for triple-negative breast cancer.
Topics: Animals; Cancer Vaccines; Chitosan; Dendritic Cells; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Nanoparticles; Triple Negative Breast Neoplasms | 2023 |
Green synthesis of chitosan/silver nanocomposite using kaempferol for triple negative breast cancer therapy and antibacterial activity.
Topics: Anti-Bacterial Agents; Chitosan; Humans; Kaempferols; Metal Nanoparticles; Microbial Sensitivity Tests; Nanocomposites; Silver; Staphylococcus aureus; Triple Negative Breast Neoplasms | 2023 |
Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Chitosan; Cyclosporine; Delayed-Action Preparations; Drug Carriers; Humans; Hyaluronan Receptors; Hyaluronic Acid; Nanoparticles; Triple Negative Breast Neoplasms | 2023 |
Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Chitosan; Dasatinib; Drug Carriers; Humans; Nanoparticles; Particle Size; Rhodamines; Triple Negative Breast Neoplasms | 2024 |
A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Mice; Nanoparticles; Rats; Rats, Wistar; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2019 |
Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Drug Synergism; Female; Gemcitabine; Humans; Hydrogels; Kinetics; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2020 |
Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells.
Topics: Cell Line, Tumor; Chitosan; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Targeting; Humans; Nanomedicine; Nanoparticles; Peptides; RNA Interference; RNA, Small Interfering; Single-Chain Antibodies; Transfection; Triple Negative Breast Neoplasms | 2020 |
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Female; Humans; Hyaluronan Receptors; Liposomes; Mice, Nude; Middle Aged; Molecular Docking Simulation; Molecular Targeted Therapy; Neoplastic Stem Cells; Positron-Emission Tomography; Radioisotopes; Tissue Distribution; Triple Negative Breast Neoplasms; Xanthones; Xenograft Model Antitumor Assays; Zirconium | 2020 |
Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Chitosan; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nitroimidazoles; Oligosaccharides; Optical Imaging; Phosphoramide Mustards; Photochemotherapy; Photosensitizing Agents; Prodrugs; Triple Negative Breast Neoplasms | 2021 |
Responsive Nanomicellar Theranostic Cages for Metastatic Breast Cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Delivery Systems; Female; Humans; Immunoconjugates; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Inbred BALB C; Mice, Nude; Micelles; Theranostic Nanomedicine; Triple Negative Breast Neoplasms | 2018 |
Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis.
Topics: Cell Line, Tumor; Chitosan; Cytosol; Drug Compounding; Female; Gene Transfer Techniques; Genetic Vectors; Humans; Iron; Metal Nanoparticles; Models, Molecular; Peptides; Polyethylene Glycols; RNA, Small Interfering; Transfection; Triple Negative Breast Neoplasms; Viral Envelope Proteins | 2018 |
Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.
Topics: Animals; Cell Line, Tumor; Chitosan; Doxorubicin; Female; Human Umbilical Vein Endothelial Cells; Humans; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Suramin; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chitosan; Curcumin; Female; Humans; Mesenchymal Stem Cells; Mice; Nanoparticles; Placenta; Pregnancy; TNF-Related Apoptosis-Inducing Ligand; Triple Negative Breast Neoplasms | 2018 |
Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Topics: Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chitosan; Doxorubicin; Drug Delivery Systems; Endocytosis; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Light; Mice; MicroRNAs; Molecular Sequence Data; Nanoparticles; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; RNA Stability; Scattering, Radiation; Solvents; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Chitosan; Endocytosis; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Transfer Techniques; Gold; Humans; Hyperthermia, Induced; Intracellular Space; Nanotubes; Phototherapy; Tissue Distribution; Triple Negative Breast Neoplasms | 2015 |
Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy.
Topics: Acrylic Resins; Antineoplastic Combined Chemotherapy Protocols; Chitosan; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Nanoparticles; Oligopeptides; Quercetin; Silicon Dioxide; Topotecan; Triple Negative Breast Neoplasms | 2016 |